Roth MKM Resumes Coverage of LeMaitre With Buy Rating
Navigating 4 Analyst Ratings For LeMaitre Vascular
LeMaitre Vascular Analyst Ratings
Lemaitre Vascular's Dominant Market Position and Growth Prospects Garner 'Buy' Rating
Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $79
J.P. Morgan Securities: Maintaining the LeMaitre Vascular (LMAT.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $72.00 to $77.00.
LeMaitre Vascular Analyst Ratings
Barrington Boosts Price Target on LeMaitre Vascular to $79 From $69, Keeps Outperform Rating
Buy Rating Affirmed: LeMaitre Vascular's Strong Performance and Upward Financial Trajectory
KeyBanc Keeps Their Hold Rating on Lemaitre Vascular (LMAT)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Stifel: Raised LeMaitre Vascular (LMAT.US) rating, adjusted from holding to buying, and adjusted target price from $59.00 to $75.00.
LeMaitre Vascular Analyst Ratings
Buy Rating Affirmed: LeMaitre Vascular's Growth and Profitability Outlook
Barrington Raises Price Target on LeMaitre Vascular to $69 From $66, Keeps Outperform Rating
Lemaitre Vascular's Strong Performance and Positive Outlook Justify Buy Rating
Lemaitre Vascular (LMAT) Receives a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Lemaitre Vascular (LMAT) and Agilon Health (AGL)
Analysts' Top Healthcare Picks: Lemaitre Vascular (LMAT), Silk Road Medical (SILK)
LeMaitre Vascular Analyst Ratings